| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 731 | 2021 |
| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the … L Emmett, J Buteau, N Papa, D Moon, J Thompson, MJ Roberts, K Rasiah, ... European urology 80 (6), 682-689, 2021 | 292 | 2021 |
| Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 268 | 2020 |
| 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity CA Chang, DA Pattison, RW Tothill, G Kong, TJ Akhurst, RJ Hicks, ... Cancer Imaging 16, 1-12, 2016 | 185 | 2016 |
| Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma G Kong, S Grozinsky-Glasberg, MS Hofman, J Callahan, A Meirovitz, ... The Journal of Clinical Endocrinology & Metabolism 102 (9), 3278-3287, 2017 | 160 | 2017 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 144 | 2022 |
| 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor … RJ Hicks, P Jackson, G Kong, RE Ware, MS Hofman, DA Pattison, ... Journal of Nuclear Medicine 60 (6), 777-785, 2019 | 122 | 2019 |
| Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol A Iravani, B Solomon, DA Pattison, P Jackson, A Ravi Kumar, G Kong, ... Thyroid 29 (11), 1634-1645, 2019 | 100 | 2019 |
| TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Lancet 397 (10276), 797-804, 2021 | 90 | 2021 |
| TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC … MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020 | 79 | 2020 |
| 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer MJ Roberts, A Morton, P Donato, S Kyle, DA Pattison, P Thomas, ... European journal of nuclear medicine and molecular imaging 48, 477-482, 2021 | 78 | 2021 |
| Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer DA Pattison, M Debowski, B Gulhane, EG Arnfield, AM Pelecanos, ... European journal of nuclear medicine and molecular imaging 49 (2), 763-776, 2022 | 69 | 2022 |
| Clinical insignificance of [18F] PSMA-1007 avid non-specific bone lesions: a retrospective evaluation EG Arnfield, PA Thomas, MJ Roberts, AM Pelecanos, SC Ramsay, CY Lin, ... European Journal of Nuclear Medicine and Molecular Imaging 48 (13), 4495-4507, 2021 | 65 | 2021 |
| Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non‐metastatic prostate cancer: implementation of standardized management guidelines AS Cheung, D Pattison, I Bretherton, R Hoermann, D Lim Joon, E Ho, ... Andrology 1 (4), 583-589, 2013 | 65 | 2013 |
| TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 40 (16_suppl), 5000-5000, 2022 | 59 | 2022 |
| Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase … MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, ... The Lancet Oncology 25 (1), 99-107, 2024 | 55 | 2024 |
| High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide … G Kong, J Callahan, MS Hofman, DA Pattison, T Akhurst, M Michael, P Eu, ... European journal of nuclear medicine and molecular imaging 44, 476-489, 2017 | 54 | 2017 |
| UpFrontPSMA: a randomized phase 2 study of sequential 177Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial … N Dhiantravan, L Emmett, AM Joshua, DA Pattison, RJ Francis, S Williams, ... BJU international 128 (3), 331-342, 2021 | 51 | 2021 |
| Molecular imaging in the investigation of hypoglycaemic syndromes and their management DA Pattison, RJ Hicks Endocrine-related cancer 24 (6), R203-R221, 2017 | 49 | 2017 |
| 18F-FDG–avid thyroid incidentalomas: the importance of contextual interpretation DA Pattison, M Bozin, A Gorelik, MS Hofman, RJ Hicks, A Skandarajah Journal of Nuclear Medicine 59 (5), 749-755, 2018 | 44 | 2018 |
